Clinical Trials Browser

Recruiting × Male Urogenital Diseases × Genitourinary × Clear all

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06353906 2025-12-08

PRIAM

Phase 2 Recruiting

27 enrolled

Genitourinary

Penile Neoplasms, Urogenital Neoplasms, Urologic Neoplasms, Male Urogenital Diseases

NCT06676527 2025-12-05

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

Recruiting

39 enrolled

Genitourinary

Urogenital Diseases, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06785636 2025-11-14

P300

Phase 1/2 Recruiting

252 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06190899 2025-03-21

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

54 enrolled

Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT06706921 2024-11-27

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Phase 4 Recruiting

15 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Clinical Trials

STRIKE-001

PRIAM

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

P300

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer